Read Larry Connors' blog – Short Term Trading Strategies
According to the company, the GE Innova cardiovascular x-ray system continues to deliver excellent image quality with dose efficiency. Those technologies will soon be further aided by the new Innova Dose, Innova 3D and Innova with Stent Technologies 1 features. Designed to further improve on the dose efficiency technologies, GE's Innova Dose package delivers superb image quality and custom dose management.
Intended to enhance, but not replace, 2D fluoroscopic imaging, GE's new Innova 3D imaging technique lets clinicians acquire and reconstruct 3D cardiac anatomy images right in the cath lab. Innova with Stent Technologies1 simplifies lesion assessment and provides exceptional stent visualization, with one-button activation and can be fully integrated with Innova IVUS systems, the company said.
GE's Vivid i compact cardiovascular ultrasound system, with its excellent imaging capability, intuitive user-interface and portable design, has led the industry in quality performance and clinical expansion, according to the company. At this year's TCT, it adds 2D Intracardiac Echo (ICE) to its repertoire, introducing high performance ultrasound imagine in a space saving design. Through an expanded partnership with Biosense Webster, GE adds the AcuNav 2D ICE catheter to Vivid i for invasive echocardiography procedures. This catheter enables the user to evaluate cardiac anatomy structures, guide ablation procedures and reduce the likelihood of complications during interventional procedures. The new product will be aimed at both the structural heart and electrophysiology markets, according to the company.
GE Healthcare and intravascular ultrasound (IVUS) company Boston Scientific announced a collaboration that enables improved IVUS workflow between the GE Healthcare Innova Cardiovascular X-ray System and the Boston Scientific iLab Ultrasound Imaging System. The iLab and Innova Systems are both featured on the show floor, the company said.
The Boston Scientific iLab Ultrasound Imaging System can be directly installed into the cardiac catheterization lab or radiology suite alongside the GE Innova X-ray System, enabling physicians to more readily incorporate IVUS technology into their procedures. With IVUS, a tiny catheter is inserted into the heart or into a vessel where high-frequency sound waves reflect off tissue or vessel walls. The reflected sound waves create a cross-sectional image from within the vessel or heart to aid in visualizing vessel and heart structure. IVUS is an important tool in determining treatment options because it is designed to offer a more complete picture from inside the artery or vessel and helps to optimize stent outcomes.
According to the company, customers can now benefit from improved workflow in the EP and cath labs due to cooperation and compatibility between GE's Innova cardiovascular imaging systems and Hansen Medical Systems' robotic navigation technology. Hansen's Sensei Robotic catheter system is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability, even during complex cardiac arrhythmia procedures. The Innova and Sensei systems work in conjunction at Boston's Brigham and Women's Hospital.
"The workflow is much improved and the compatibility has been seamless," said Dr. Laurence Epstein, Director of Brigham and Women's Electrophysiology Lab. "Combining the imaging excellence of Innova with the precision guidance of Hansen's robotics is truly helping us maximize patient care and minimize procedure time."
To expand its compatibility with the industry leaders in FFR technology, GE Healthcare said that it is announcing a newly formed collaboration with Radi Medical Systems (Uppsala, Sweden). "Combining the strength of GE's Mac-Lab IT hemodynamic recording cardiovascular platform and the performance of Radi's Pressurewire Aeris in the assessment of FFR has great clinical potential," said Pascale Witz, vice president of GE Healthcare's Interventional Cardiology business. "We're pleased to enter into a relationship that expands the clinical capabilities of our systems with new possibilities."
((Comments on this story may be sent to newsdesk@closeupmedia.com))
((Distributed via M2 Communications Ltd - http://www.m2.com))
http://www.10meters.com
Comments on this story may be sent to newsdesk@closeupmedia.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
